Media coverage about Galena Biopharma (NASDAQ:GALE) has trended positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galena Biopharma earned a coverage optimism score of 0.31 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 83 out of 100, indicating that recent news coverage is very likely to have an effect on the company’s share price in the near future.

These are some of the news stories that may have effected Accern’s scoring:

A number of brokerages have recently weighed in on GALE. Zacks Investment Research upgraded Galena Biopharma from a “hold” rating to a “strong-buy” rating and set a $0.75 target price on the stock in a report on Monday, March 20th. ValuEngine downgraded Galena Biopharma from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

Galena Biopharma (NASDAQ GALE) traded down 1.02% during trading on Friday, reaching $0.58. The company had a trading volume of 258,460 shares. The company has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.97. Galena Biopharma has a 52-week low of $0.52 and a 52-week high of $11.18. The company’s market capitalization is $21.71 million.

Galena Biopharma (NASDAQ:GALE) last released its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.13. During the same period in the previous year, the company earned ($0.07) earnings per share. On average, equities analysts forecast that Galena Biopharma will post ($0.56) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/07/16/galena-biopharma-gale-receiving-positive-press-coverage-report-shows-updated-updated-updated.html.

About Galena Biopharma

Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.

Insider Buying and Selling by Quarter for Galena Biopharma (NASDAQ:GALE)

Receive News & Stock Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related stocks with our FREE daily email newsletter.